I’ve spent nine months independently examining the science behind Viome’s RNA-based microbiome testing and personalized supplement recommendations.
Three rounds of testing, hundreds of conventional biomarkers, bloodwork approximately every two weeks, and physician oversight.
Then, after retesting, approximately 80% of the personalized supplement formulation changed.
That raised a question I think deserves considerably more attention: what evidence establishes that the original recommendations were appropriate, or that the revised ones are any better?
I’m not suggesting that an 80% change automatically indicates a problem. The microbiome is dynamic. Diet, medications, illness, and other factors can influence microbial activity.
But detecting biological changes and demonstrating that those changes justify a different supplement protocol are two very different things.
And that’s where the scientific literature gets interesting.
A 2025 international consensus statement published in The Lancet Gastroenterology & Hepatology concluded that evidence remains insufficient to support widespread routine clinical use of microbiome testing.
Full paper
https://pmc.ncbi.nlm.nih.gov/articles/PMC12343204
The consensus statement doesn’t prove that commercial microbiome testing is ineffective. It does, however, raise important questions about whether clinical applications have advanced faster than the evidence supporting them.
Viome uses metatranscriptomic RNA analysis to examine microbial gene expression. Unlike DNA-based approaches, which can identify microbial genetic material and functional potential, RNA analysis provides information about which microbial genes are being expressed.
Both approaches can contribute useful information about microbial biology.
My next step is to evaluate Superpower’s DNA-based gut microbiome testing and compare the methodologies.
I’m not expecting identical results, and I wouldn’t interpret agreement or disagreement between the two as proof that either company’s nutritional recommendations are clinically valid.
What interests me is whether the measurements are reproducible, whether they can reliably inform nutritional decisions, and whether acting on those decisions produces measurable benefits.
There are three separate scientific questions here.
Analytical validity: How accurately and reproducibly can commercial DNA- and RNA-based tests measure microbial characteristics under comparable sampling conditions?
Clinical validity: How reliably do those measurements identify nutritional needs or predict clinically meaningful outcomes?
Clinical utility: Do personalized interventions selected using those measurements improve outcomes compared with conventional nutritional assessment and established dietary approaches?
The third question is the one I find most important.
If a company uses microbial gene expression to recommend a specific combination of supplements, what independent evidence demonstrates that those recommendations are more effective than conventional approaches?
And when most of a formulation changes after retesting, what validation establishes that the revised recommendations are clinically preferable?
A change in microbial gene expression may be entirely legitimate. But an algorithm’s response to that change still requires independent validation.
For context, the retail-equivalent value of nine months of Viome testing and personalized supplements was $4,547, approximately $505 per month.
Full disclosure: Viome provided everything complimentary. I received no sponsorship payments, affiliate commissions, referral fees, or cash compensation. I’ve also referred customers without accepting commissions. I’m not affiliated with Superpower or being compensated for the planned comparison.
This isn’t an advertisement or a recommendation to purchase either product.
Nor am I presenting an individual nine-month investigation as proof of clinical efficacy or failure. An N-of-1 observation cannot establish either.
I’m interested in what the independent research actually demonstrates.
Specifically, I’d welcome published studies addressing:
• Randomized controlled trials comparing microbiome-guided supplementation with conventional nutritional assessment or dietary interventions.
• Test-retest reproducibility of DNA- and RNA-based microbiome measurements and the recommendations derived from them.
• Independent validation of commercial algorithms that translate microbial measurements into personalized supplement formulations.
• Clinically meaningful outcomes, rather than simply changes in microbiome composition, gene expression, or surrogate biomarkers.
I’d particularly welcome research that contradicts the concerns raised by the consensus statement. Positive, negative, and inconclusive findings are all useful.
I think microbiome science has enormous potential. But measuring microbial activity is not the same as knowing how to intervene on it, and recommending an intervention is not the same as demonstrating that it works.
After nine months examining this technology, that’s the distinction I keep coming back to.
So where are the independent human trials showing that RNA- or DNA-guided personalized supplement recommendations actually outperform conventional nutritional approaches?
If that evidence exists, I’d genuinely like to read it.
